February 4th, 2012
(APDN.OB) Applied DNA Sciences Moves Forward Within Government, Banking, And Insurance Industries
Posted on 16. Mar, 2011 by PublicWire
(PublicWire.com News Release) Applied DNA Sciences, Inc. (OTCQB:APDN), announces new customers and inquiries within the governments and the banking and insurance industries.
Applied DNA provides DNA markers to protect cash and valuables in transit (CViT), to protectbrand owners, and to secure legitimate supply chains against the diversion to gray markets and against the infiltration of counterfeit products. The company’s approach to each vertical market has been to sell its unique, uncopyable DNA tags to suppliers whose components enter at the bottom or through multiple points within a supply chain, and then license the platform to “pain
points” that experience the most liability.
Licensing Model Similar to Software Industry
For example, within the cash transportation industry, APDN sells its DNA markers to the security ink users, ATM cassette manufacturers, and cash box manufacturers, who supply their DNA-enhanced products to security companies and ATM owners. However, the security value in the event of theft can only be realized if the risk-owner has licensed the platform from APDN.
License Unlocks the DNA Sequence Key
“Our model is similar to that employed by the software industry,” said Dr. James Hayward, CEO of APDN. “We ensure widespread deployment of our DNA marks within an industry, in the same manner as software developers distribute software via laptops and device manufacturers. Our licensees can only realize the value of the DNA markers, just as software must be licensed to enjoy its value.” He continued: “Our DNA sequence content is only available to our licensees.
We maintain control of our sequences, and only we can authenticate the cash stolen and provide forensic support in an act perpetrated against a risk-owner, which is initially the cash-intransit transporter, but ultimately includes the financial institution and their insurer.”
APDN now has a proven track record within the CViT industry. With over 22 convictions to its credit, APDN has a 100% conviction record for captured criminals who have stolen cash from its security licensees within the UK. The result, the deterrence provided by APDN, yielded a significant drop in attacks and eliminated cash losses more than one hundred times the cost of annual licensing.
Proven Return on Investment
This proven ROI has brought APDN customers higher up the risk chain. “Banks, insurers and governments are now recognizing the deterrence that can only be provided by DNA markers,” said Dr. Hayward. “We have received initial orders from governments and insurers, and we are fielding inquiries from banks internationally. The increased demand contributed to the closing of the best quarter in our company’s history, announced in SEC filings that describe our first FY11 quarter, ending December 2010.”
About APDN
APDN sells patented DNA security solutions that provide anti-counterfeit protection, as well as protecting brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used for product authentication in a unique manner that essentially cannot be copied. When used in conjunction with other law enforcement technologies, SigNature DNA can provide a forensic chain of evidence that has been used successfully in more than 22 convictions. To learn more, go to www.adnas.com where APDN routinely posts all press releases.
The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to ur short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K, filed on December 15, 2010 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.
SOURCE Applied DNA Sciences, Inc.
INVESTOR CONTACT: Debbie Bailey, 631-444-8090, fax: 631-444-8848
MEDIA CONTACT: Janice Meraglia, 631-444-6293, fax: 631-444-8848
FCMN Contact: info@adnas.com
Web site: http://www.adnas.com
Trading Symbols
Applied DNA Sciences trades Over The Counter As APDN (OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN)
About PublicWire.com
PublicWire.com is a Small Cap Financial Press Release Company that uses a variety of cutting edge methods to syndicate your Small Cap Press Release to various news and information outlets. Our press releases have consitantly placed the Small Cap Companies we work with on the first result page of major search engines such as Google, Bing, and Yahoo. We work exclusively with Pinksheet and Over The Counter (PK and OTCBB) Companies to ensure maximum exposure for their Press Releases.
To maximize your OTCBB / Pinksheet / Small Cap Company Press Release, call us directly at 407-218-7446.
OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN
The symbols “OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN” reflect the variety of methods APDN lists their stock as, and were valid at the time of original publication of this press release.
(PublicWire.com News Release) Applied DNA Sciences, Inc. (OTCQB:APDN), announces new customers and inquiries within the governments and the banking and insurance industries.
Applied DNA provides DNA markers to protect cash and valuables in transit (CViT), to protectbrand owners, and to secure legitimate supply chains against the diversion to gray markets and against the infiltration of counterfeit products. The company’s approach to each vertical market has been to sell its unique, uncopyable DNA tags to suppliers whose components enter at the bottom or through multiple points within a supply chain, and then license the platform to “pain
points” that experience the most liability.
Licensing Model Similar to Software Industry
For example, within the cash transportation industry, APDN sells its DNA markers to the security ink users, ATM cassette manufacturers, and cash box manufacturers, who supply their DNA-enhanced products to security companies and ATM owners. However, the security value in the event of theft can only be realized if the risk-owner has licensed the platform from APDN.
License Unlocks the DNA Sequence Key
“Our model is similar to that employed by the software industry,” said Dr. James Hayward, CEO of APDN. “We ensure widespread deployment of our DNA marks within an industry, in the same manner as software developers distribute software via laptops and device manufacturers. Our licensees can only realize the value of the DNA markers, just as software must be licensed to enjoy its value.” He continued: “Our DNA sequence content is only available to our licensees.
We maintain control of our sequences, and only we can authenticate the cash stolen and provide forensic support in an act perpetrated against a risk-owner, which is initially the cash-intransit transporter, but ultimately includes the financial institution and their insurer.”
APDN now has a proven track record within the CViT industry. With over 22 convictions to its credit, APDN has a 100% conviction record for captured criminals who have stolen cash from its security licensees within the UK. The result, the deterrence provided by APDN, yielded a significant drop in attacks and eliminated cash losses more than one hundred times the cost of annual licensing.
Proven Return on Investment
This proven ROI has brought APDN customers higher up the risk chain. “Banks, insurers and governments are now recognizing the deterrence that can only be provided by DNA markers,” said Dr. Hayward. “We have received initial orders from governments and insurers, and we are fielding inquiries from banks internationally. The increased demand contributed to the closing of the best quarter in our company’s history, announced in SEC filings that describe our first FY11 quarter, ending December 2010.”
About APDN
APDN sells patented DNA security solutions that provide anti-counterfeit protection, as well as protecting brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used for product authentication in a unique manner that essentially cannot be copied. When used in conjunction with other law enforcement technologies, SigNature DNA can provide a forensic chain of evidence that has been used successfully in more than 22 convictions. To learn more, go to www.adnas.com where APDN routinely posts all press releases.
The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to ur short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K, filed on December 15, 2010 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.
SOURCE Applied DNA Sciences, Inc.
INVESTOR CONTACT: Debbie Bailey, 631-444-8090, fax: 631-444-8848
MEDIA CONTACT: Janice Meraglia, 631-444-6293, fax: 631-444-8848
FCMN Contact: info@adnas.com
Web site: http://www.adnas.com
Trading Symbols
Applied DNA Sciences trades Over The Counter As APDN (OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN)
About PublicWire.com
PublicWire.com is a Small Cap Financial Press Release Company that uses a variety of cutting edge methods to syndicate your Small Cap Press Release to various news and information outlets. Our press releases have consitantly placed the Small Cap Companies we work with on the first result page of major search engines such as Google, Bing, and Yahoo. We work exclusively with Pinksheet and Over The Counter (PK and OTCBB) Companies to ensure maximum exposure for their Press Releases.
To maximize your OTCBB / Pinksheet / Small Cap Company Press Release, call us directly at 407-218-7446.
OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN
The symbols “OTCBB:APDN, APDN.OB, APDN.OTCBB, APDN” reflect the variety of methods APDN lists their stock as, and were valid at the time of original publication of this press release.
(BCLI.OB) BrainStorm Presents at Inaugural Stem Cell Investor and Executive Networking Conference
Posted on 02. Jun, 2010 by PublicWire in Medical
(PublicWire.com Press Release) — BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI – News), a leading developer of adult stem cell technologies and therapeutics Tuesday announced that Rasheda Ali, a member of BrainStorm’s advisory board and Professor Eldad Melamed, BrainStorm’s Chief Medical Advisor, will be presenting at Tuesday’s Inaugural Stem Cell Investor and Executive Networking Conference Event from 11:00 a.m. to 4:00 p.m. (EDT), at National Securities Corporation Global Headquarters at 120 Broadway, (2nd Floor Conference Center) in New York City.
At the conference, Rasheda Ali, the revered author and daughter of renowned boxer Muhammad Ali, will provide remarks at 11:00 AM and discuss BrainStorm and its upcoming ALS clinical trials.
Professor Eldad Melamed, the former Head of Neurology, Rabin Medical Center, and Tel-Aviv University, and a member of the Scientific Committee of the Michael J. Fox Foundation for Parkinson’s Research, will panel a session titled “Autologous Approaches” at 2:00 PM discussing BrainStorm’s approach to treating ALS patients.
The Stem Cell Investor & Executive Networking Conference Event, hosted by National Securities Corporation and MD Becker Partners, is strategically designed to unite investors with industry executives to exchange information and highlight opportunities in the expanding stem cell universe. The event will bring together the founding visionary researchers, clinicians, entrepreneurs, key investors, and other stakeholders to offer compelling panel discussions, share information, and discuss the future of the field. For more information on the conference please go to http://www.mdbpartners.com/science.
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, former Head of Neurology at Rabin Medical Center, and cell biologist Prof. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company’s current focus is on ALS, although its technology has promise for treating several other diseases including MS, Huntington’s disease and stroke.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include risks associated with BrainStorm’s limited operating history, history of losses; minimal working capital, dependence on its license to Ramot’s technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.
Contacts
BrainStorm Cell Therapeutics
Rami Efrati, CEO, +972-3-9236384
efrati@brainstorm-cell.com